According to a new study by the University of Pennsylvania and the RAND Corporation, US workers still lack the tools to accurately track the rise of fentanyl.
“What I’m hearing is that there’s a huge disconnect between what workers are reporting and what we’re seeing,” said RAND’s Michael E. Carle, one of the authors of the study.
“And that’s not just anecdotal, but it’s a consistent pattern across the industries and across all the different measures we’re using to look at the crisis.”
The RAND study found that, by the end of January, the number of cases in the US had increased to 9,400, a number that has increased every month since the beginning of the year.
The most recent count, from November, put the number at 13,900.
The study found the trend in the number was particularly pronounced among the least-educated, those with a high school diploma or less, while the number in the top 20 percent of income earners grew by nearly 8 percent from the end.
The RAND report also found that people working in the private sector were still struggling with the increased prevalence of the opioid, which is used in the manufacturing of the drug fentanyl.
In the study, RAND researchers analyzed data from a survey of more than 2,000 people from across the country, including people working as janitors, cashiers and others.
They also looked at drug use and related data from police and health department records.
The researchers found that the rate of drug-related deaths in the workforce increased by an average of 13 percent over the past year.
They attributed the increase to people working longer hours, including those who work overtime, while using the drug at work.
The trend has been noted by some federal and state officials who have been trying to find solutions to the crisis, including President Donald Trump and Attorney General Jeff Sessions.
The number of fatal overdoses in the United States has more than doubled since 2013.
According to the CDC, the drug is most commonly found in the form of a synthetic opioid, often called a fentanyl analog.
Fentanyl analogs, or “fake” opioid painkillers, have been widely used by users to treat their addictions and other pain problems.
In recent years, they have been used to treat other diseases, including the chronic use of opioids by cancer patients.
In March, the FDA approved the use of fentanyl for the treatment of cancer pain, with some states passing new laws restricting its use.
In response, the CDC has warned that the drug poses serious health risks and that patients should stay away from it.
“Fentanyl is an increasingly potent and potentially lethal opioid, and while it is not a new drug, it has rapidly evolved into a potent and highly toxic opioid with potential long-term health consequences for those who take it,” the agency said in a statement in April.
According the CDC’s latest update on fentanyl, the rate at which new cases of the synthetic opioid were reported to health departments has been rising rapidly since 2014, and by more than 50 percent since the start of 2017.
The number of new fentanyl-related death cases in states including Michigan, Illinois and Kentucky rose by nearly 3,000 from January to March, according to the study conducted by the RAND researchers.
But the number still remained relatively low compared to the increase in other diseases.